pyrazines has been researched along with Armstrong Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furuta, Y; Gowen, BB; Hickerson, BT; Jung, KH; Komeno, T; Westover, JB | 1 |
| Basler, M; Beck, U; Groettrup, M; Lauer, C | 1 |
2 other study(ies) available for pyrazines and Armstrong Syndrome
| Article | Year |
|---|---|
Effective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients.
Topics: Amides; Animals; Antiviral Agents; Disease Models, Animal; Female; Immunocompromised Host; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Male; Mice, Inbred NZB; Pyrazines; Ribavirin; Survival Analysis; Transplant Recipients; Treatment Outcome; Viral Load | 2018 |
The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Epitopes; Interferon-gamma; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Mice; Mice, Inbred C57BL; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2009 |